Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience.
Qingyan LiuRong LiLingling LiGaokun WangShiyu JiXuan ZhengXiaodong JiaHaitao TaoYi HuPublished in: Therapeutic advances in medical oncology (2023)
showed significantly better survival benefits than PD-1 monotherapy.